The FDA’s vaccine advisory panel on Thursday opened the path for fall COVID-19 shots targeting XFG, a fast-growing variant that now makes up more than half of new U.S. infections. For clinicians, the vote signals likely strain updates ahead of respiratory virus season, even as available data suggest XFG is not causing more severe illness than earlier variants.

The Move

• The Vaccines and Related Biological Products Advisory Committee recommended updating this fall’s COVID-19 vaccines to target XFG, nicknamed “stratus.”

• All but one panel member voted in favor; one member abstained, citing limited evidence that an XFG-targeted shot is overwhelmingly better than current formulations.

• The recommendation is intended to let manufacturers prepare doses for fall and winter, when cases typically rise.

• The decision now goes to the FDA, which is expected to authorize manufacturers to begin production.

Why it Matters for Care

• Clinicians should expect likely updated vaccine formulations for the 2026 fall campaign and patient questions about whether this year’s shot is “different.”

• CDC data presented to the panel showed the highest hospitalization rates last season were in infants younger than 6 months and adults 65 and older.

• XFG and its descendants accounted for more than half of U.S. infections as of May 8; XFG.1.1 alone accounted for about 1 in 4 infections.

• Symptoms appear similar to earlier strains, including sore throat, cough, headache, body aches, fever, and chills.

Between the Lines

• The vote reflects a familiar vaccine-strain strategy: update to the variant gaining dominance because immune escape, not necessarily greater virulence, is driving concern.

• Mouse data from Moderna and Sanofi suggested XFG-targeted vaccines generated higher antibody levels against several circulating strains than the current LP.8.1 formulation; Pfizer said its XFG candidate and current shot produced similar antibody levels.

• That split helps explain the lone abstention and underscores how thin the evidence base can be before manufacturers must lock in fall production.

• Politically, the meeting came just after FDA Commissioner Marty Makary’s resignation, though the session had been scheduled beforehand and officials said his departure did not affect it.

What to Watch

• Whether the FDA formally signs off on XFG-based formulations and how quickly manufacturers move into production.

• Who approves the final decision inside the agency, given the FDA currently lacks both a permanent commissioner and a permanent vaccine chief; acting Commissioner Kyle Diamantas is in place.

• Whether CDC messaging and payer coverage align quickly enough to support fall uptake, especially for older adults and other high-risk groups.

• How closely U.S. policy tracks the World Health Organization, which recommended LP.8.1 or other closely related circulating variants, including XFG.

Source: NBC News Health